Description: AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Home Page: www.ab-science.com
3, Avenue George V
Paris,
75008
France
Phone:
33 1 47 20 00 14
Officers
| Name | Title |
|---|---|
| Mr. Alain Moussy MBA | Co-Founder, Chairman, Pres, CEO, MD & Scientific Director |
| Mr. Laurent Guy MBA | Chief Financial Officer |
| Mr. Christian FASSOTTE | Global Chief Medical Officer |
| Mr. Alexis BERNARD | Head of Veterinary Sales |
| Mr. Harshad KULKARNI | Head of Statistics |
| Dr. Yves Grumser M.D. | Head of Clinical Safety & Pharmacovigilance |
| Dr. Albert Ahn D.V.M. | Pres of USA Operations |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 193.6581 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 100 |